BeiGene Joins Antibody-Drug Conjugate Stampede With DualityBio Deal
The deal, focused on a preclinical candidate and worth more than $1bn, follows DualityBio’s licensing agreement in April with BioNTech, amid growing interest among drug makers in ADCs.
